This activity is part of the Multidisciplinary Breast Pathology (MBP) learning series. Save 10% when you purchase all of the courses in this series together. Below are the courses included in the series. Click here to see all courses in the series.
- 2018 HER2 Focused Update
- Diagnosing and Classifying Hyperplasia, Atypical Hyperplasia and Low Grade DCIS
- Diagnosing Breast Lesions
- Getting Your Message Across: Effective Communication Strategies for Breast Pathologists
- Invasive Breast Cancer and Risk of Recurrence Testing
- Understanding Breast Imaging Terminology
This activity originally released as Invasive Breast Cancer and Risk of Recurrence Testing and was available between July 1, 2020, and June 30, 2023. The content was reviewed in November 2022.
Genomic testing for breast cancer recurrence risk has become an important part of clinical breast cancer care. This activity provides an overview of risk of recurrence testing used in the diagnosis and treatment of invasive breast cancer. Statistics on cancer recurrence and clinical outcomes with chemotherapy, including data from the TAILORx trial, are reviewed. The activity also provides the value and benefits of risk of recurrence testing, as well as how to determine which patients are good candidates for this testing. The different types of multigene assays and distinctions between them are reviewed, as well as an overview of IHC and protein profiling of cancer. The activity includes ASCO and NCCN clinical practice guidelines for use of biomarkers to guide decisions on adjuvant systemic therapy for women with invasive breast cancer, and discusses the issues and concerns that continue to exist around risk of recurrence testing.
After completing this activity, you should be able to:
- Define risk of recurrence testing.
- Describe the value and benefits of risk of recurrence testing.
- Identify several of the commercial multigene assays available and some distinctions between them.
- Explain which patients are good candidates for risk of recurrence testing and how to make this determination.
- Explain when and how the application of selective antibody panels and routine IHC can be used to predict clinical behavior and outcomes in subsets of breast cancer patients.
- Identify the clinical practice guidelines for use of biomarkers to guide decisions on adjuvant systemic therapy for women with invasive breast cancer.
- Explain some of the current issues and concerns surrounding risk of recurrence testing for breast cancer patients.
David G. Hicks, MD, FCAP
Bradley M. Turner MD, MPH, MHA, FCAP
Accreditation: The College of American Pathologists (CAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Category 1: The College of American Pathologists designates this internet enduring material educational activity for a
maximum of 1.5
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To pay with a check, print a copy of this page and send it with your check to the address below. You will be notified when your payment has been processed and you have been registered into the activity.
College of American Pathologists
325 Waukegan Road
Northfield, IL 60093-2750
Refunds will be handled on an exception basis. Please submit your request to the CAP in writing via email at
firstname.lastname@example.org or fax at 847-832-8006.
Pop-up blockers must be turned off.
The CAP recognizes that some Veteran’s Administration, US Government, and military participants may have difficulty accessing the online activity. If you experience difficulty or have any questions, please contact a representative of the Customer Contact Center at 800-323-4040 option 1 or email@example.com.
This activity and evaluation are available June 29, 2023, and expire June 29, 2026, at 11:59 PM (CT). Upon completion of the activity your credit will be awarded. Your certificate may be downloaded from your Transcript.